← All institutions

J.P. Morgan

303 reports

Reports from this institution

J.P. Morgan

J.P. Morgan: Kolon Biotech’s phase III lung cancer data: progression-free survival extended, with the efficacy advantage driven by more durable disease control

OptiTROP-Lung06 showed that sac-TMT plus pembrolizumab achieved median progression-free survival of 15.0 months in first-line treatment of PD-L1-negative advanced non-squamous non-small cell lung cancer, versus 5.7 months in the control group. JPMorgan is optimistic about its first-line treatment opportunity, but overall survival data remain immature, and median progression-free survival may fluctuate as the data mature.

J.P. Morgan

J.P. Morgan: Akeso’s phase III biliary tract cancer trial meets survival endpoint, but strong control arm narrows relative advantage

Ivonescimab plus chemotherapy extended median overall survival by 2.8 months compared with durvalumab plus chemotherapy. The result was statistically significant but fell short of JPMorgan’s previous optimistic scenario. Phase II lung cancer data for another PD-1/VEGF bispecific antibody support the drug class; the competitive landscape remains to be clarified by phase III data.

J.P. Morgan

J.P. Morgan: North American metals earnings diverge: steelmakers benefit from delayed price increases, aluminum processors struggle with execution, and gold miners face greater cost scrutiny

JPMorgan believes steelmakers can still benefit from price pass-through in the fourth quarter, although leading indicators for construction are weakening. Demand and earnings performance vary across aluminum processors, while gold equities require a comparison of costs, valuations and the timing of growth delivery.

J.P. Morgan

J.P. Morgan: Upgrading Unitree by two notches: With a breakthrough expected sooner, how will platform value be realized?

JPMorgan upgraded Unitree from Underweight to Overweight and raised its price target from 300 yuan to 995 yuan. The shift reflects expectations of an earlier breakthrough in embodied AI, rising hardware platform value and a longer scarcity premium associated with its listed status. The key hurdles are converting pilots into repeat purchases, deploying reliably and monetizing the ecosystem.

J.P. Morgan

J.P. Morgan: After the safe-haven rally in Treasuries, why does JPMorgan still expect yields to rise and the curve to steepen?

Pressure on French government bonds and weakness in technology stocks drove Treasuries higher, but JPMorgan believes near-term valuations have become expensive and prefers a trade betting on a wider spread between 10-year and 30-year yields. Auction data show that foreign and long-end demand remains strong, although buyers have become more price-sensitive across most maturities.

J.P. Morgan

J.P. Morgan: Safe-haven demand lifts Treasuries as credit risks diverge: Why does JPMorgan still expect yields to rise slightly?

Pressure on European sovereign bonds and concerns over AI valuations are driving safe-haven demand for US Treasuries, but JPMorgan believes the 10-year yield is already about 15 basis points below its model-implied fair value. Credit market pressure is concentrated in major cloud providers and lower-rated bonds, while ABS and agency CMBS are relatively resilient.

J.P. Morgan

J.P. Morgan: Crypto spot ETPs see 738 million dollars in outflows in a single day, while flows remain positive for the week

JPMorgan estimates that US crypto spot ETPs recorded combined net outflows of 738 million dollars on 22 October, mostly from Bitcoin products. Falling cryptocurrency prices coincided with increased redemptions, but net inflows for the week through that day remained at 216 million dollars; trading volumes in Bitcoin and Ether products were also below their respective daily averages since launch.